Miraca Life Sciences Announces Significant American College of Gastroenterology Tradeshow Plans

Inform Diagnostics, the leading pathology services provider that collaborates to make patients and practices better, today announced that it will have a significant presence at the American College of Gastroenterology (ACG tradeshow), the annual scientific meeting for GI professionals October 11 – 16th in San Diego, CA.

In addition to participating in the Exhibitor Hall, Inform Diagnostics will be offering an informative presentation on Meaningful Use compliance for the first 100 participants in the Exhibitor Theater on Tuesday, October 15th at 1:40 pm. At this presentation, Inform Diagnostics will help GI physicians advance their workflow efficiency toward full EHR integration and offer guidance on forthcoming regulatory concerns to successfully attest to Meaningful Use requirements.

Visitors to Inform Diagnostics’ booth, # 1015, can learn how to leverage MMR IHC testing to identify patients at risk for having Lynch Syndrome. Hereditary nonpolyposis colon cancer (HNPCC), also known as Lynch syndrome, is an inherited cancer that predisposes patients to the development of colorectal, endometrial, gastric, upper urinary tract, and other cancers. Visitors to booth # 1015 can learn how to evaluate tumors for the characteristics common to individuals with HNPCC/Lynch syndrome which include microsatellite instability and loss of protein expression of one or more of the genes associated with HNPCC/Lynch syndrome.

“Inform Diagnostics has a responsibility to doctors and patients to deliver reliable, meaningful laboratory results because effective patient care stems from accurate interpretation and diagnosis, so we’ll be introducing a number of exciting innovations,” said Dr. Amy Noffsinger, Medical Director for Inform Diagnostics.

In addition, seven abstracts submitted by Inform Diagnostics’ pathologists to the American College of Gastroenterology were accepted for posters. The posters that will be presented at ACG by Inform Diagnostics this year include:

  • Eosinophilic Esophagitis is Associated with an Increased Prevalence of Inflammatory Bowel Disease
  • Intestinal Spirochetosis is Associated with Diarrhea, Weight Loss, and Abdominal Pain in Less Than Half of the Infected Subjects: A Study of 447 Patients and 1.2 Million Controls
  • Esophageal Eosinophilia and Gastric Mucosal Pathology: Is There a Link?
  • Unexpected Candidiasis in the Endoscopically Normal Esophagus
  • Helicobacter negative Chronic Active Gastritis is a Distinct Nosologic Entity, Not Simply Missed Helicobacter Infection
  • Low Prevalence of Colon Polyps in Patients with Diarrhea and Microscopic Colitis
  • Gastric Pathology in HIV-Infected Patients

“Inform Diagnostics understands every biopsy represents a patient apprehensively awaiting an answer, and Inform Diagnostics believes every patient deserves the right answer. The right answer is more than a diagnosis; it is specific, accurate, sophisticated, and actionable medical information derived from collaboration by the best subspecialist pathologists,” said Dr. Noffsinger. “Our ‘customer first’ approach is the real driver behind our innovation, and we’re very excited about the many opportunities we have to showcase our new solutions in 2013.”

About Inform Diagnostics
Inform Diagnostics specializes in the development and commercialization of the highest quality academic pathology services, primarily in the fields of dermatology, hematology, gastroenterology and urology. The company’s core team of more than 70 academic-caliber specialists utilize state-of-the-art pathology laboratories currently headquartered in Irving, Texas, and throughout the United States to serve more than 3,500 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Inform Diagnostics continuously improves diagnostic precision.

About Inform Diagnostics Holdings
With group net sales of ¥192.2 billion (FYE 3/2013), Inform Diagnostics Holdings, a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, is engaged in the business consisting of three segments: (i) development, manufacture, and commercialization of in vitro diagnostics, (ii) clinical laboratory testing, and (iii) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc,. a leading supplier of in vitro diagnostics in Japan, and SRL, Inc. (“SRL”), Japan’s largest commercial laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing, including gene-based tests.

About ACG
The American College of Gastroenterology is a recognized leader in educating GI professionals and the general public about digestive disorders. Our mission: to serve the evolving needs of physicians in the delivery of high quality scientific, humanistic and cost-effective health care to gastroenterology patients.

Media Contact:

Linda Fisk
lfisk@MiracaLS.com
214-596-2262 office
214-846-2599 cell

Categories: Press